Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

Sanofi is ending a Phase 2 clinical trial that's testing a drug from Denali for multiple sclerosis, ending the development ...

The FDA has approved Roche’s inavolisib plus Pfizer's Ibrance and fulvestrant in a subtype of breast cancer over a month ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup ...

Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an ...

Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the ...

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from ...

When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in ...

Plus, news about Booster Therapeutics, Century Therapeutics and Holobiome: Ono Pharmaceutical’s ADC deal: The Japanese drugmaker will pay up to $700 million to LigaChem Biosciences to develop, produce ...

The activist investor targeting Pfizer claims that the company's former CEO and CFO, who were previously working with the ...